Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamide SCHEMBL10722500 | 0.92 | BLM (0.60) | BLMKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL4228629 | 0.88 | ALDH1A1 (0.57) | BLMKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL10727700 | 0.86 | KMT2A (0.69) | BLMKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL14595391 | 0.85 | LMNA (0.62) | BLMKMT2AALDH1A1MEN1HSD11B1 | |
| SCHEMBL252026 | 0.84 | HPGD (0.79) | BLMKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL7129676 | 0.84 | HPGD (0.79) | BLMKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL10294623 | 0.84 | ALDH1A1 (0.59) | KDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10195012 | 0.84 | ALDH1A1 (0.72) | KDM4EKMT2AALDH1A1MEN1LMNA | |
| SCHEMBL10293583 | 0.84 | MEN1 (0.66) | BLMKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL3694268 | 0.83 | BLM (0.67) | BLMKDM4EKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833144-B2 | Treating autoimmune disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230201192-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2023-06-29 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-20170226073-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2015022546-A1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-02-19 | — | — | WO | disclosed |
| EP-1633712-B1 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013090696-A1 | CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090197891-A1 | Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease | SAMARITAN PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| CN-101022806-A | Use of (4-alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease | SAMARITAN PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | CN | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1755605-A2 | USE OF (4-ALKYLPIPERAZINYL)(PHENYL) METHANONES IN THE TREATMENT OF ALZHEIMER'S DISEASE | Samaritan Pharmaceuticals, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
| WO-2005108378-A2 | USE OF (4-ALKYLPIPERAZINYL) (PHENYL) METHANONES IN THE TREATMENT OF ALZHEIMER’S DISEASE | SAMARITAN PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | BLM 2030/4885KDM4E 1813/4885KMT2A 3410/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | BLM 4802/4885KDM4E 2846/4885KMT2A 1973/4885 |
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | KCNK3, KCNQ3, ACKR3 | BLM 2349/4885KDM4E 2581/4885KMT2A 1238/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | BLM 3373/4885KDM4E 3250/4885KMT2A 3389/4885 |
| US-20230201192-A1 | METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER | SCD, SCD5, SPTLC1 | BLM 2838/4885KDM4E 1537/4885KMT2A 4099/4885 |
| US-20170226073-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | BLM 2613/4885KDM4E 2575/4885KMT2A 3484/4885 |
| US-11833144-B2 | Treating autoimmune disease | NR5A1, SSB, RBP4 | BLM 4199/4885KDM4E 1717/4885KMT2A 3628/4885 |
| US-20090197891-A1 | Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease | APP, PSEN1, PSEN2 | BLM 4745/4885KDM4E 2581/4885KMT2A 3737/4885 |
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | BLM 3429/4885KDM4E 1024/4885KMT2A 1896/4885 |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | BLM 136/4885KDM4E 1465/4885KMT2A 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.